{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:18:15Z","timestamp":1792297095477,"version":"4.4.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Drugs that affect the renin-angiotensin system, such as angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors are not typically recommended for pregnant women because of their potential fetal toxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case study:<\/jats:title>\n            <jats:p>A 32-year-old pregnant woman with nephrotic syndrome lasting more than 5\u200ayears became pregnant for the first time. She had been taking losartan tablets before and during pregnancy. Ultrasound at 24<jats:sup>+2<\/jats:sup>\u200aweeks of pregnancy showed oligohydramnios, and the maximum vertical depth of amniotic fluid volume was 1.4\u200acm. Follow-up ultrasound examinations every 2 weeks showed persistent oligohydramnios [amniotic fluid volume: 1.1\u20133.4\u200acm, amniotic fluid index 1.9\u20136.9\u200acm]. B-ultrasound at 30<jats:sup>+2<\/jats:sup>\u200aweeks showed slightly enhanced fetal renal cortex echo. The patient was treated at 32<jats:sup>+2<\/jats:sup>\u200aweeks of pregnancy at our hospital.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Nephrotic syndrome and oligohydramnios.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Losartan was discontinued and replaced by nifedipine controlled-release tablets to lower blood pressure. The amount of amniotic fluid gradually increased to normal levels within 8 days. The patient was discharged at 33<jats:sup>+2<\/jats:sup>\u200aweeks of pregnancy for follow-up. At 34<jats:sup>+4<\/jats:sup>\u200aweeks, blood pressure had increased to 177\/113\u200amm Hg and the patient was re-hospitalized with nephrotic syndrome complicated by preeclampsia. Due to progression of severe preeclampsia, elective cesarean section was performed at 35<jats:sup>+3<\/jats:sup>\u200aweeks. After delivery, losartan and nifedipine were prescribed to continue lowering blood pressure. The patient was discharged 4 days after surgery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Losartan use was terminated at 32<jats:sup>+2<\/jats:sup>\u200aweeks of pregnancy. Amniotic fluid returned to normal after 8\u200adays and the baby was delivered after 22\u200adays. At last follow-up, the infant was 24\u200amonths old and healthy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Although ARBs are effective for treating hypertension, they should be replaced by other classes of anti-hypertensive drugs in pregnant women. Pregnant women who elect to continue using ARBs should be informed about risks, they should be carefully monitored during pregnancy, and their pregnancy should be allowed to proceed as long as clinically feasible in order to optimize maternal and infant outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000024304","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T13:50:47Z","timestamp":1611409847000},"page":"e24304","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Use of angiotensin II receptor blocker during pregnancy"],"prefix":"10.1097","volume":"100","author":[{"given":"Qiang","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-fan","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-mei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-rong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"R1-20250504","first-page":"28","article-title":"Guidelines for appropriate drug use for hypertension (2nd Edition)","volume":"9","year":"2017","journal-title":"Chin J Front Med (Electronic Edition)"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00392-017-1095-0","article-title":"Hypertension up to date: SPRINT to SPYRAL","volume":"106","author":"Kulenthiran","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00392-015-0939-8","article-title":"General practitioners\u2019 adherence to chronic heart failure guidelines regarding medication: the GP-HF study","volume":"105","author":"Hirt","year":"2016","journal-title":"Clin Res Cardiol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00392-017-1170-6","article-title":"Heart failure with preserved ejection fraction: current management and future strategies: expert opinion on the behalf of the Nucleus of the \u201cHeart Failure Working Group\u201d of the German Society of Cardiology (DKG)","volume":"107","author":"Tschope","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013\u200aESH\/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"e36171","DOI":"10.1371\/journal.pone.0036171","article-title":"Hypertension in women of reproductive age in the United States: NHANES 1999-2008","volume":"7","author":"Bateman","year":"2012","journal-title":"PLoS One"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/VHRM.S15541","article-title":"A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors","volume":"7","author":"Siragy","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/bdra.23027","article-title":"Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence","volume":"94","author":"Polifka","year":"2012","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"212","DOI":"10.2215\/CJN.04740510","article-title":"Effect of drugs on renal development","volume":"6","author":"Schreuder","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000211324","article-title":"The kidney from prenatal to adult life: perinatal programming and reduction of number of nephrons during development","volume":"30","author":"Puddu","year":"2009","journal-title":"Am J Nephrol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/10641950601147937","article-title":"Angiotensin II receptor blockers in pregnancy: a case report and systematic review of the literature","volume":"26","author":"Vel\u00e1zquez-Armenta","year":"2007","journal-title":"Hypertens Pregnancy"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/14767050500217244","article-title":"Fetal and neonatal consequences of antenatal exposure to type 1 angiotensin II receptor-antagonists","volume":"18","author":"Vendemmia","year":"2005","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"d6667","DOI":"10.1136\/bmj.d6667","article-title":"Fetal risk from ACE inhibitors in the first trimester","volume":"343","author":"Mitchell","year":"2011","journal-title":"BMJ"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00392-018-1234-2","article-title":"Pregnancy outcome after first trimester use ofangiotensin AT1 receptor blockers: an observational cohort study","volume":"107","author":"Hoeltzenbein","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1161\/HYPERTENSIONAHA.112.196352","article-title":"Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review","volume":"60","author":"Bullo","year":"2012","journal-title":"Hypertension"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/hr.2015.12","article-title":"Outcomes of 83 fetuses exposed to angiotensin receptor blockers during the second or third trimesters: a literature review","volume":"38","author":"Shimada","year":"2015","journal-title":"Hypertens Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T07:01:41Z","timestamp":1746342101000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024304"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000024304","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]},"assertion":[{"value":"2020-10-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}